Show simple item record

dc.contributor.authorBergman, Olle
dc.date.accessioned2009-11-13T12:34:00Z
dc.date.available2009-11-13T12:34:00Z
dc.date.issued2009-11-13T12:34:00Z
dc.identifier.isbn978-91-628-7938-9
dc.identifier.urihttp://hdl.handle.net/2077/21077
dc.description.abstractRationale: Dopamine synthesizing neurons are involved in a wide variety of functions. The most prominent dopamine pathways originate in the midbrain. The development, function and survival of these dopaminergic neurons are under the influence of numerous transcription and neurotrophic factors. Subtle differences in the genes encoding these factors may be of importance for several psychiatric and neurodegenerative disorders. LMX1A, LMX1B and PITX3 are transcription factors that are essential for the development, specification and survival of midbrain dopaminergic neurons. BDNF is a neurotrophic factor involved in neurodevelopmental processes including differentiation and survival of dopaminergic neurons. Another protein of importance for dopaminergic neurotransmission is the dopamine transporter (DAT) that mediates reuptake and inactivation of extracellular dopamine and is hence of fundamental importance in regulating dopamine transmission. The specific aim of this thesis was to investigate the possible influence of polymorphisms in these dopamine-related genes on dopamine-related disorders, i.e. Parkinson’s disease (PD), attention-deficit/hyperactivity disorder (ADHD), social anxiety disorder (SAD) and schizophrenia. Observations: Three single nucleotide polymorphisms (SNPs) in LMX1A and one in LMX1B were associated with PD. After splitting for gender, six SNPs were associated with PD in women and four in men (Paper I). Two SNPs in PITX3 were associated with PD in patients with an early age of onset when compared either to controls or to PD patients with late onset (Paper II). One of the PITX3 polymorphisms was also associated with schizophrenia, as were two polymorphisms in LMX1A, and one SNP in LMX1B (Paper III). We assessed longitudinal, quantitative phenotypes of hyperactivity-impulsivity and inattention, and found that the Met allele of the Val66Met polymorphism in the BDNF gene was associated with increased persistent hyperactivity-impulsivity symptoms as well as with increased age-specific inattention symptoms (Paper IV). The amygdala, essential for detection of biologically relevant stimuli and fear generation, is under excitatory influence of dopamine. Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) were used to investigate if a variable number of tandem repeat (VNTR) polymorphism in the DAT gene (SLC6A3) influences amygdala function during processing of aversive emotional stimuli in SAD patients and healthy controls, respectively. The 9-repeat allele was associated with significantly increased amygdala activity, as assessed with PET, across tests (i.e. public speaking, processing of angry and neutral faces) in SAD patients, but with decreased amygdala activity in controls. Moreover, 9-repeat carriers, regardless of diagnosis, displayed augmented amygdala reactivity, i.e. a greater activation, of the left amygdala in response to angry compared to neutral faces. Blood oxygen level-dependent (BOLD) fMRI was used to assess healthy volunteers, and in line with the results from the PET study, 9-repeat carriers displayed higher reactivity of the left amygdala in response to angry faces, compared to neutral geometric shapes (Paper V). Conclusions: All of the studies were based on a priori hypotheses regarding the possible relationship between the genes and the disorders under investigation. Some of the associations reported in this thesis have not been described earlier, others have been confirmed in independent samples, whereas in some cases, earlier studies have been inconclusive. In summary, our results support the notion that variation in dopamine-related genes is of importance for dopamine-related disorders and amygdala function.en
dc.language.isoengen
dc.relation.haspartI: PITX3 polymorphism is associated with early onset Parkinson’s disease. Olle Bergman, Anna Håkansson, Lars Westberg, Kajsa Nordenström, Andrea Carmine Belin, Olof Sydow, Lars Olson, Björn Holmberg, Elias Eriksson and Hans Nissbrandt. Neurobiology of Aging (2008) Apr 16 (Epub. ahead of print). ::pmid::18420308en
dc.relation.haspartII: Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson’s disease? Olle Bergman, Anna Håkansson, Lars Westberg, Andrea Carmine Belin, Olof Sydow, Lars Olson, Björn Holmberg, Laura Fratiglioni, Lars Bäckman, Elias Eriksson, Hans Nissbrandt. Journal of Neural Transmission (2009) 116:333–338 ::pmid::19189040en
dc.relation.haspartIII: Polymorphisms in dopamine-related transcription factors LMX1A, LMX1B and PITX3 are associated with schizophrenia. Olle Bergman, Lars Westberg, Lars-Göran Nilsson, Rolf Adolfsson and Elias Eriksson. Preliminary manuscript.en
dc.relation.haspartIV: Association of brain-derived neurotrophic factor polymorphism with the developmental course of attention-deficit/hyperactivity disorder. Olle Bergman, Lars Westberg, Paul Lichtenstein, Elias Eriksson and Henrik Larsson. Submitted manuscript.en
dc.relation.haspartV: Amygdala function is associated with a dopamine transporter gene polymorphism in patients with social anxiety disorder and healthy controls. Olle Bergman, Fredrik Åhs, Tomas Furmark, Lieuwe Appel, Clas Linnman, Vanda Faria, Stephen B. Manuck, Robert E. Ferrell, Ahmad Hariri, Susanne Henningsson, Mats Fredrikson, Elias Eriksson, and Lars Westberg. Submitted manuscript.en
dc.subjectdopamineen
dc.subjectneurodevelopmenten
dc.subjectamygdalaen
dc.subjectschizophreniaen
dc.subjectParkinson's diseaseen
dc.subjectsocial anxiety disorderen
dc.subjectADHDen
dc.subjectPITX3en
dc.subjectLMX1Aen
dc.subjectLMX1Ben
dc.subjectBDNFen
dc.subjectDATen
dc.subjectSNPen
dc.subjectgenesen
dc.subjectgeneticsen
dc.subjectBDNFen
dc.titleOn the influence of dopamine-related genetic variation on dopamine-related disordersen
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.gup.mailolle.bergman@pharm.gu.seen
dc.type.degreeDoctor of Philosophy (Medicine)en
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academyen
dc.gup.departmentInstitute of Neuroscience and Physiology. Department of Pharmacologyen
dc.gup.defenceplaceTorsdagen den 26 november 2009, kl. 9.00, Hörsal LNC, Medicinaregatan 13, Göteborgen
dc.gup.defencedate2009-11-26
dc.gup.dissdb-fakultetSA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record